AVTX

Avalo Therapeutics, Inc. [AVTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AVTX Stock Summary

Top 10 Correlated ETFs

AVTX


Top 10 Correlated Stocks

AVTX


In the News

11:02 28 Mar 2024 AVTX

Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know

Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

08:16 28 Mar 2024 AVTX

New Strong Buy Stocks for January 3rd

GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.

07:31 28 Mar 2024 AVTX

New Strong Buy Stocks for December 14th

MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.

08:16 28 Mar 2024 AVTX

New Strong Buy Stocks for November 27th

VVI, AVTX, RYI, TM and HIBB have been added to the Zacks Rank #1 (Strong Buy) List on November 27, 2023.

08:16 28 Mar 2024 AVTX

New Strong Buy Stocks for November 21st

AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.

11:26 28 Mar 2024 AVTX

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.

06:30 28 Mar 2024 AVTX

3 Hot Penny Stocks To Watch Before Next Week

Are you looking for the best penny stocks to buy after the stock market dropped today? Believe it or not there are plenty of cheap stocks to watch that are heading higher amid this big drop in major indexes.

01:54 28 Mar 2024 AVTX

3 Penny Stocks To Buy For Under $1, Are They Worth The Risk?

Penny stocks priced at less than one dollar seem very appealing. Just a small investment could potentially lead to huge returns.

12:47 28 Mar 2024 AVTX

Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs

Avalo (AVTX) will receive an upfront payment of $150,000 on selling three compounds to AUG Therapeutics. The company is also eligible to receive milestone payments of up to $45 million.

07:00 28 Mar 2024 AVTX

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

AVTX Financial details

Company Rating
Neutral
Market Cap
3.91M
Income
-33.19M
Revenue
2.25M
Book val./share
0.31
Cash/share
0.22
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-11.75
Forward P/E
-1.28
PEG
1.6
P/S
2.97
P/B
26.54
P/C
97.36
P/FCF
-0.21
Quick Ratio
1.95
Current Ratio
2.11
Debt / Equity
0.04
LT Debt / Equity
-
-
-
EPS (TTM)
-2.59
EPS next Y
-16.8
EPS next Q
-4.8
EPS this Y
-54.38%
EPS next Y
548.64%
EPS next 5Y
548.65%
EPS last 5Y
-20.35%
Revenue last 5Y
-0.3%
Revenue Q/Q
-63.3%
EPS Q/Q
-81.36%
-
-
-
-
SMA20
75%
SMA50
16.67%
SMA100
-72%
Inst Own
738%
Inst Trans
0.89%
ROA
-113%
ROE
1404%
ROC
-1.23%
Gross Margin
6%
Oper. Margin
-1269%
Profit Margin
-1475%
Payout
-
Shs Outstand
801.61K
Shs Float
801.61K
-
-
-
-
Target Price
-
52W Range
3.95-1130.4
52W High
-98.1%
52W Low
+614%
RSI
49
Rel Volume
384.5
Avg Volume
49.8K
Volume
19.15M
Perf Week
379.19%
Perf Month
350%
Perf Quarter
-36.25%
Perf Half Y
-45.25%
-
-
-
-
Beta
0.687
-
-
Volatility
5.84%, 3.03%
Prev Close
350.95%
Price
21.42
Change
341.19%

AVTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
6.321.421.090.621.92
Net income per share
-13.82-3.42-10.52-9.71-4.43
Operating cash flow per share
-1.08-4.02-6.62-8.16-2.84
Free cash flow per share
-1.27-4.07-6.63-8.17-2.85
Cash per share
3.672.363.096.281.4
Book value per share
7.224.414.012.66-1.16
Tangible book value per share
-9.230.871.40.99-2.69
Share holders equity per share
7.224.414.012.66-1.16
Interest debt per share
5.030.030.43.562.51
Market cap
26.96B73.95B46.55B42.53B11.38B
Enterprise value
26.96B73.94B46.53B42.5B11.39B
P/E ratio
-673.02-4.54K-723.03-504.16-273.19
Price to sales ratio
1.47K10.96K6.95K7.88K630.46
POCF ratio
-8.62K-3.86K-1.15K-599.86-425.42
PFCF ratio
-7.3K-3.81K-1.15K-598.9-423.92
P/B Ratio
1.29K3.52K1.9K1.84K-1.04K
PTB ratio
1.29K3.52K1.9K1.84K-1.04K
EV to sales
1.47K10.95K6.95K7.87K630.81
Enterprise value over EBITDA
4.15K-4.26K-1.85K-527.43-304.28
EV to operating cash flow
-8.62K-3.86K-1.15K-599.55-425.66
EV to free cash flow
-7.3K-3.81K-1.15K-598.6-424.15
Earnings yield
00000
Free cash flow yield
00000
Debt to equity
0.740.010.11.44-1.78
Debt to assets
0.2200.060.420.58
Net debt to EBITDA
0.730.130.730.27-0.17
Current ratio
0.841.461.713.110.74
Interest coverage
48.440034.35-8.98
Income quality
0.081.190.640.840.64
Dividend Yield
00000
Payout ratio
0-0.070-0.39-0.36
Sales general and administrative to revenue
0.581.52.64.041.14
Research and developement to revenue
0.321.744.8111.081.73
Intangibles to total assets
0.680.470.370.180.43
Capex to operating cash flow
0.180.01000
Capex to revenue
-0.03-0.04-0.01-0.02-0.01
Capex to depreciation
-0.12-0.07-0.03-0.07-0.57
Stock based compensation to revenue
0.130.381.011.510.42
Graham number
47.3718.430.8124.110.75
ROIC
-1.08-0.79-0.94-1.44-4.15
Return on tangible assets
-1.77-0.84-2.32-1.28-2.2
Graham Net
-10.930.010.490.12-3.15
Working capital
-4.28M5.56M10.78M41.96M-5.7M
Tangible asset value
-26.74M4.16M8.57M8.64M-25.32M
Net current asset value
-27.41M2.61M6.81M4.71M-27.87M
Invested capital
0.740.010.11.44-1.78
Average receivables
6.15M6.93M4.81M4.59M3.36M
Average payables
1.37M1.76M2.33M2.97M3.13M
Average inventory
746.47K565.89K12K20.5K29K
Days sales outstanding
171.81283.51238.92324.538.8
Days payables outstanding
70.5865.223.13K824.74306.33
Days of inventory on hand
54.220.663.659.32.13
Receivables turnover
2.121.291.531.129.41
Payables turnover
5.175.60.120.441.19
Inventory turnover
6.73553.7810039.24171.7
ROE
-1.92-0.77-2.62-3.653.82
Capex per share
-0.19-0.06-0.01-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.590.10.040.050.01
Net income per share
0.34-1.04-0.85-0.59-0.11
Operating cash flow per share
0.61-0.42-0.86-0.79-0.15
Free cash flow per share
0.6-0.42-0.87-0.78-0.15
Cash per share
1.81.41.420.450.22
Book value per share
-0.22-1.16-0.53-0.50.31
Tangible book value per share
-1.75-2.69-1.76-1.530.01
Share holders equity per share
-0.22-1.16-0.53-0.50.31
Interest debt per share
2.122.221.771.12-0.02
Market cap
7.5B11.39B4.92B1.19B1.36B
Enterprise value
7.5B11.4B4.93B1.2B1.35B
P/E ratio
587.46-290.31-123.65-36.32-64.94
Price to sales ratio
501.7512.72K10.37K1.85K5.75K
POCF ratio
1.31K-2.89K-489.81-107.96-198.66
PFCF ratio
1.32K-2.85K-482.23-109.53-198.66
P/B Ratio
-3.7K-1.04K-785.63-170.8292.41
PTB ratio
-3.7K-1.04K-785.63-170.8292.41
EV to sales
501.8912.72K10.37K1.86K5.71K
Enterprise value over EBITDA
1.83K-1.29K-558.7-168.62-359.57
EV to operating cash flow
1.31K-2.89K-490.12-108.72-197.25
EV to free cash flow
1.32K-2.85K-482.53-110.3-197.25
Earnings yield
000-0.010
Free cash flow yield
000-0.01-0.01
Debt to equity
-9.4-1.83-3.15-2.10.04
Debt to assets
0.520.60.550.60.02
Net debt to EBITDA
0.52-0.77-0.35-1.172.57
Current ratio
1.070.740.830.332.11
Interest coverage
3.56-9.33-9.26-7.182.41
Income quality
1.790.41.011.351.31
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.223.295.673.7610.52
Research and developement to revenue
0.476.8912.657.245.29
Intangibles to total assets
0.390.430.40.590.49
Capex to operating cash flow
-0.010.010.02-0.010
Capex to revenue
0-0.06-0.330.250
Capex to depreciation
-1.15-1.6-4.793.850
Stock based compensation to revenue
0.050.941.81.394.04
Graham number
1.285.213.22.570.89
ROIC
0.18-0.93-0.63-0.87-0.24
Return on tangible assets
0.14-0.52-0.46-0.83-0.35
Graham Net
-2.19-3.15-2.15-1.78-0.07
Working capital
1.3M-5.7M-3.99M-14.94M6.65M
Tangible asset value
-16.44M-25.32M-20.68M-21.38M286K
Net current asset value
-19.13M-27.87M-23.25M-23.69M-1.92M
Invested capital
-9.4-1.83-3.15-2.10.04
Average receivables
1.58M1.62M1.39M450.5K791K
Average payables
1.81M2.16M4.22M3.16M770K
Average inventory
22.5K21K19.5K18.5K9.5K
Days sales outstanding
7.91192.76162.386.16586.53
Days payables outstanding
246.65418.35908.9895.47287.49
Days of inventory on hand
3.752.93.12.290.36
Receivables turnover
11.380.470.5514.610.15
Payables turnover
0.360.220.10.940.31
Inventory turnover
24312939.33247
ROE
-1.570.91.591.18-0.36
Capex per share
0-0.01-0.010.010

AVTX Frequently Asked Questions

What is Avalo Therapeutics, Inc. stock symbol ?

Avalo Therapeutics, Inc. is a US stock , located in Rockville of Md and trading under the symbol AVTX

What is Avalo Therapeutics, Inc. stock quote today ?

Avalo Therapeutics, Inc. stock price is $21.42 today.

Is Avalo Therapeutics, Inc. stock public?

Yes, Avalo Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap